{"id":384178,"date":"2020-11-18T10:19:14","date_gmt":"2020-11-18T15:19:14","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=384178"},"modified":"2020-11-18T10:19:14","modified_gmt":"2020-11-18T15:19:14","slug":"tiziana-life-sciences-plc-tiziana-or-the-company-pdmr-dealing","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-plc-tiziana-or-the-company-pdmr-dealing\/","title":{"rendered":"Tiziana Life Sciences PLC\u00a0(“Tiziana” or the “Company”) –\u00a0PDMR Dealing"},"content":{"rendered":"
\n

LONDON and NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) — Tiziana Life Sciences plc (Nasdaq: TLSA \/ AIM: TILS) (“Tiziana<\/strong>” or the “Company<\/strong>“), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 45,000 ordinary shares of 3p each in the market at a price of 84p per share.<\/p>\n

The acquisition takes Mr Cerrone’s interests from 34.029% to 34.052% (within the 1% incremental threshold under Note 11 to Rule 9 of the UK Takeover Code).<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
1.<\/td>\nDetails of PDMR \/ person closely associated<\/td>\n<\/tr>\n
a)<\/td>\nName<\/p>\n<\/td>\nGabriele Cerrone<\/td>\n<\/tr>\n
2.<\/td>\nReason for the notification<\/p>\n<\/td>\n<\/tr>\n
a)<\/td>\nPosition \/ status<\/p>\n<\/td>\nExecutive Chairman<\/td>\n<\/tr>\n
b)<\/td>\nInitial notification \/amendment<\/p>\n<\/td>\nInitial notification<\/td>\n<\/tr>\n
3.<\/td>\nDetails of the issuer<\/p>\n<\/td>\n<\/tr>\n
a)<\/td>\nName<\/p>\n<\/td>\nTiziana Life Sciences plc<\/td>\n<\/tr>\n
b)<\/td>\nLEI<\/p>\n<\/td>\n213800CED47HI8PIOB36<\/td>\n<\/tr>\n
4.<\/td>\nDetails of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type\u00a0 of transaction; (iii) each date; and (iv) each place where transactions have\u00a0 been conducted<\/td>\n<\/tr>\n
a)<\/td>\nDescription of the financial instrument<\/p>\n<\/td>\nOrdinary Shares of 3p each<\/td>\n<\/tr>\n
b)<\/td>\nIdentification code of the Financial Instrument<\/p>\n<\/td>\nISIN for Tiziana Life Sciences plc: GB00BKWNZY55<\/td>\n<\/tr>\n
c)<\/td>\nNature of the transaction<\/p>\n<\/td>\nMarket Purchase<\/td>\n<\/tr>\n
d)<\/td>\nPrice(s) and volume(s)<\/td>\n84p <\/p>\n

45,000<\/td>\n<\/tr>\n

f)<\/td>\nDate of the transaction<\/p>\n<\/td>\n18 November 2020<\/td>\n<\/tr>\n
g)<\/td>\nPlace of the transaction<\/p>\n<\/td>\nXLON \u00a0<\/td>\n<\/tr>\n<\/table>\n

\n About Tiziana Life Sciences<\/strong>\n <\/p>\n

Tiziana Life Sciences plc is a dual listed (NASDAQ: TLSA & UK AIMS: TILS) biotechnology company that focuses on the discovery and development of novel molecules to treat human diseases in oncology, inflammation and infectious diseases. In addition to milciclib, the Company will be shortly initiating phase 2 studies with orally administered foralumab for Crohn\u2019s Disease and nasally administered foralumab for progressive multiple sclerosis. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) in clinical development in the world. This phase II compound has potential application in a wide range of autoimmune and inflammatory diseases, such as Crohn\u2019s Disease, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.<\/p>\n

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596\/2014. The person who arranged the release of this information is Keeren Shah, Finance Director of Tiziana.<\/p>\n

\n
\n For further enquiries:<\/u>
\n <\/strong>\n <\/p>\n

United Kingdom Investors:<\/p>\n\n\n\n\n\n\n\n
\n Tiziana Life Sciences plc<\/strong>
\n
Gabriele Cerrone, Chairman and founder<\/td>\n		\u00a0<\/td>\n+44 (0)20 7495 2379<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Cairn Financial Advisers LLP<\/strong> (Nominated Adviser)
Liam Murray \/ Jo Turner<\/td>\n		\u00a0<\/td>\n+44 (0)20 7213 0880<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Optiva<\/strong>
\n Securities Limited (Broker)<\/strong>
\n
Robert Emmet<\/td>\n		\u00a0<\/td>\n+ 44 (0)20 3981 4173<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

United States Investors:<\/p>\n\n\n
Dave Gentry
RedChip Companies Inc.<\/td>\n		\u00a0<\/td>\nOffice 1 800 RED CHIP (733 2447)
Cell 407-491-4498 (USA)
dave@redchip.com<\/a><\/td>\n<\/tr>\n<\/table>\n

\u00a0<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

LONDON and NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) — Tiziana Life Sciences plc (Nasdaq: TLSA \/ AIM: TILS) (“Tiziana” or the “Company“), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 45,000 ordinary shares of 3p each in the market at a price of 84p per share. The acquisition takes Mr Cerrone’s interests from 34.029% to 34.052% (within the 1% incremental threshold under Note 11 to Rule 9 of the UK Takeover Code). 1. Details of PDMR \/ person closely associated a) Name Gabriele Cerrone 2. Reason for the notification … <\/p>\n

Continue reading “Tiziana Life Sciences PLC\u00a0(“Tiziana” or the “Company”) –\u00a0PDMR Dealing”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-384178","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nTiziana Life Sciences PLC\u00a0("Tiziana" or the "Company") -\u00a0PDMR Dealing - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-plc-tiziana-or-the-company-pdmr-dealing\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tiziana Life Sciences PLC\u00a0("Tiziana" or the "Company") -\u00a0PDMR Dealing - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LONDON and NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) — Tiziana Life Sciences plc (Nasdaq: TLSA \/ AIM: TILS) (“Tiziana” or the “Company“), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 45,000 ordinary shares of 3p each in the market at a price of 84p per share. The acquisition takes Mr Cerrone’s interests from 34.029% to 34.052% (within the 1% incremental threshold under Note 11 to Rule 9 of the UK Takeover Code). 1. Details of PDMR \/ person closely associated a) Name Gabriele Cerrone 2. Reason for the notification … Continue reading "Tiziana Life Sciences PLC\u00a0(“Tiziana” or the “Company”) –\u00a0PDMR Dealing"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-plc-tiziana-or-the-company-pdmr-dealing\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-18T15:19:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODUwMyMzODMzNzU5IzIxMjM4ODU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-plc-tiziana-or-the-company-pdmr-dealing\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-plc-tiziana-or-the-company-pdmr-dealing\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Tiziana Life Sciences PLC\u00a0(“Tiziana” or the “Company”) –\u00a0PDMR Dealing\",\"datePublished\":\"2020-11-18T15:19:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-plc-tiziana-or-the-company-pdmr-dealing\\\/\"},\"wordCount\":461,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-plc-tiziana-or-the-company-pdmr-dealing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4ODUwMyMzODMzNzU5IzIxMjM4ODU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-plc-tiziana-or-the-company-pdmr-dealing\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-plc-tiziana-or-the-company-pdmr-dealing\\\/\",\"name\":\"Tiziana Life Sciences PLC\u00a0(\\\"Tiziana\\\" or the \\\"Company\\\") -\u00a0PDMR Dealing - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-plc-tiziana-or-the-company-pdmr-dealing\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-plc-tiziana-or-the-company-pdmr-dealing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4ODUwMyMzODMzNzU5IzIxMjM4ODU=\",\"datePublished\":\"2020-11-18T15:19:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-plc-tiziana-or-the-company-pdmr-dealing\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-plc-tiziana-or-the-company-pdmr-dealing\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-plc-tiziana-or-the-company-pdmr-dealing\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4ODUwMyMzODMzNzU5IzIxMjM4ODU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4ODUwMyMzODMzNzU5IzIxMjM4ODU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tiziana-life-sciences-plc-tiziana-or-the-company-pdmr-dealing\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tiziana Life Sciences PLC\u00a0(“Tiziana” or the “Company”) –\u00a0PDMR Dealing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tiziana Life Sciences PLC\u00a0(\"Tiziana\" or the \"Company\") -\u00a0PDMR Dealing - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-plc-tiziana-or-the-company-pdmr-dealing\/","og_locale":"en_US","og_type":"article","og_title":"Tiziana Life Sciences PLC\u00a0(\"Tiziana\" or the \"Company\") -\u00a0PDMR Dealing - Market Newsdesk","og_description":"LONDON and NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) — Tiziana Life Sciences plc (Nasdaq: TLSA \/ AIM: TILS) (“Tiziana” or the “Company“), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 45,000 ordinary shares of 3p each in the market at a price of 84p per share. The acquisition takes Mr Cerrone’s interests from 34.029% to 34.052% (within the 1% incremental threshold under Note 11 to Rule 9 of the UK Takeover Code). 1. Details of PDMR \/ person closely associated a) Name Gabriele Cerrone 2. Reason for the notification … Continue reading \"Tiziana Life Sciences PLC\u00a0(“Tiziana” or the “Company”) –\u00a0PDMR Dealing\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-plc-tiziana-or-the-company-pdmr-dealing\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-18T15:19:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODUwMyMzODMzNzU5IzIxMjM4ODU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-plc-tiziana-or-the-company-pdmr-dealing\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-plc-tiziana-or-the-company-pdmr-dealing\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Tiziana Life Sciences PLC\u00a0(“Tiziana” or the “Company”) –\u00a0PDMR Dealing","datePublished":"2020-11-18T15:19:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-plc-tiziana-or-the-company-pdmr-dealing\/"},"wordCount":461,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-plc-tiziana-or-the-company-pdmr-dealing\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODUwMyMzODMzNzU5IzIxMjM4ODU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-plc-tiziana-or-the-company-pdmr-dealing\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-plc-tiziana-or-the-company-pdmr-dealing\/","name":"Tiziana Life Sciences PLC\u00a0(\"Tiziana\" or the \"Company\") -\u00a0PDMR Dealing - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-plc-tiziana-or-the-company-pdmr-dealing\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-plc-tiziana-or-the-company-pdmr-dealing\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODUwMyMzODMzNzU5IzIxMjM4ODU=","datePublished":"2020-11-18T15:19:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-plc-tiziana-or-the-company-pdmr-dealing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-plc-tiziana-or-the-company-pdmr-dealing\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-plc-tiziana-or-the-company-pdmr-dealing\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODUwMyMzODMzNzU5IzIxMjM4ODU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODUwMyMzODMzNzU5IzIxMjM4ODU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tiziana-life-sciences-plc-tiziana-or-the-company-pdmr-dealing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Tiziana Life Sciences PLC\u00a0(“Tiziana” or the “Company”) –\u00a0PDMR Dealing"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/384178","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=384178"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/384178\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=384178"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=384178"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=384178"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}